MedTrace Logo

Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients

NCT04790266 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-11-18

No results posted yet for this study

Summary

To assess the role of myocardial oedema on CMR (T2 mapping) after radiation therapy and cardiotoxic systemic therapy in predicting the incidence of cardiotoxicity, defined as by consensus guidelines\* (decline of LVEF ≥10% points with a final LVEF \<53%) measured on CMR and ECHO over the time window of 12 months from the end of radiation therapy.

Conditions

Interventions

DIAGNOSTIC_TEST

Cardiac MRI

cCardiac MRI, ecocardiography and cardiotoxicity blood tests will be repeated as previously scheduled

Sponsors & Collaborators

  • Cardiocentro Ticino

    collaborator OTHER

  • North Estonia Medical Centre

    collaborator OTHER

  • Fondazione IRCCS Policlinico San Matteo di Pavia

    collaborator OTHER

  • Oncology Institute of Southern Switzerland

    lead OTHER

Principal Investigators

  • mariacarla Valli · IOSI

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-15
Primary Completion
2023-12-14
Completion
2023-12-14

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04790266 on ClinicalTrials.gov